November 20, 2018 | English | عربي
Add to Twitter
 
Initial results from EMPRISE real-world evidence study shows empagliflozin was associated with reduced risk for hospitalisation for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease
• Empagliflozin was associated with a 44 percent reduction in relative risk of hospitalization for heart failure (HHF) compared with commonly used dipeptidyl peptidase-4 inhibitors1

• Effect of empagliflozin on HHF was consistent in patients with and without established cardiovascular disease1

• Findings support data from the landmark EMPA-REG OUTCOME® trial, in which empagliflozin reduced the relative risk of HHF by 35 percent in people with type 2 diabetes and established cardiovascular disease2